Evelo Biosciences Is A Clinical Stage Biotechnology Company Based In Cambridgemassachusettsfounded In 2015It Is Publicly Traded On Nasdaq Under The Ticker Symbol Evlothe Company Is Dedicated To Developing A Unique Platform Of Orally Administered Biologics That Target Immune Cells In The Small Intestineaiming To Modulate Systemic Inflammation And Immunity Evelo S Product Pipeline Includes Several Oral Medicinessuch As Ev 101Abbv 154 Designed For Treating Inflammatory Diseasesand Ev 102Which Focuses On Immuno Oncology Applicationsadditionallyev 103 Serves As A Platform For Further Developing Oral Biologicsenhancing The Company S Capabilities In This Innovative Fieldevelo Has Established Strategic Collaborations With Major Pharmaceutical Companies To Advance Its Clinical Stage Pipeline And Support Its Mission Of Transforming Health Through Novel Treatments
